Dexpramipexole Development in Moderate-to-Severe Eosinophilic Asthma

50%

of all patients suffering with asthma have elevated numbers of eosinophils in their blood and lungs.

Elevated eosinophils are associated with allergic and other inflammatory disorders, including asthma, certain chronic gastrointestinal diseases, and hypereosinophilic syndrome (HES), a rare and sometimes fatal disorder with limited treatment options.

In the Phase 2 EXHALE trial, dexpramipexole, a small-molecule drug in pill form, demonstrated a significant, dose-dependent reduction of eosinophil counts.

Dexpramipexole reduces eosinophils in the blood and tissue by inhibiting their maturation in the bone marrow.

Eosinophil-depleting drugs have been shown to improve outcomes in patients with moderate-to-severe eosinophilic asthma.